Cumberland Pharmaceuticals to Present at Lazard Healthcare Conference in New York on November 17, 2009
More News related to CPIX
- Newly Published Acetadote(R) Data Shows Product Can Provide Substantial Cost-Savings for Healthcare Systems
- Cumberland Pharma (CPIX) Announces Positive Top-Line Results of Caldolor Injection
- Caldolor(R) (Ibuprofen) Injection Demonstrates Significant Fever Reduction in Hospitalized Burn Patients
- Morgan Joseph Reiterates a 'Buy' on Cumberland Pharmaceuticals (CPIX)
- Morning Movers 11/10: UPG, CYD, PCLN, FLL, BZH Higher; RHIE, OPXT, PRKR, PIKE, MBI, SDTH Lower
More News related to Press Releases
- A New Audio Interview with Mariner's Choice Intl. CEO Amie Hingston is now at SmallCapVoice.com
- Iams(R) Proactive Health(TM) with Prebiotics Promotes Healthy Digestion and Strong Defenses in Dogs and Cats
- Dillard's, Inc. Reports November Sales Results
- Stryker Announces $750 Million Share Repurchase Program and Declares a $0.15 Per Share Quarterly Dividend
- Colorado Goldfields Launches Series: "Milling Dynamics in the News" -- Relevant Information for Company Shareholders
NASHVILLE, Tenn., Nov. 2 /PRNewswire-FirstCall/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology markets, today announced that Chief Executive Officer A.J. Kazimi and Chief Commercial Officer Martin E. Cearnal will present an update on the company at the Lazard Healthcare Conference in New York at 10:25 a.m. Eastern Time on Tuesday, November 17, 2009.
The presentation will be simultaneously webcast and can be accessed by visiting the Investor Relations section on Cumberland Pharmaceuticals' website at www.cumberlandpharma.com. Shortly following the live webcast, a replay will be available and archived for 90 days.
About Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Inc. is a Tennessee-based specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets include hospital acute care and gastroenterology. Cumberland markets Acetadote® for the treatment of acetaminophen poisoning and Kristalose®, a prescription laxative. The Company also recently launched Caldolor®, the first injectable treatment for pain and fever approved in the United States. Cumberland is dedicated to providing innovative products which improve quality of care for patients. The Company completed its initial public offering of common stock in August 2009.
For more information on Cumberland Pharmaceuticals, please visit www.cumberlandpharma.com.
SOURCE: Cumberland Pharmaceuticals Inc.
SOURCE Cumberland Pharmaceuticals Inc.
Related Categories
Press ReleasesStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
